Not an actual patient.

ELIGARD^® is a proven, reliable, and trusted ADT¹

Proven efficacy supported by the strongest body of clinical data published in peer-reviewed journals^1-7

Backed by an established reputation for advancing the science of prostate cancer*

manuscripts published

110+

posters & oral  presentations at medical congresses

MANUSCRIPTS in progress

190+

abstracts

*Research supported by Tolmar, Inc.

ELIGARD CONTINUES TO LEAD THE WAY IN BRINGING CURRENT AND RELEVANT SCIENCE TO THE ADVANCED PROSTATE CANCER COMMUNITY

ELIGARD ACHIEVED PROFOUND T SUPPRESSION ACROSS 1-, 3-, 4-, AND 6-MONTH DOSES

Percentage of Patients Achieving Serum Testosterone Concentrations of ≤20 ng/dL Across All Studies^2†

^†Data from week 3 time point excluded as it reflects initial T surge and not final levels of suppression.¹

by day 28

94-99^%

of patients achieved T levels ≤50 ng/dL across all doses¹

at week 24

92-96^%

of patients achieved T levels <20 ng/dL across all doses²

Mean Testosterone Level (ng/dL)
Achieved Across All Doses at Study Conclusion²

low occurrence of T BREAKTHROUGHS

In the ELIGARD study population, Only

OUT OF

424

had T breakthroughs^‡ after the second dose at the 24-week time point^1,3

Achieve your PSA goals with ELIGARD¹

In all studies, ELIGARD decreased serum PSA in all patients whose baseline values were elevated above normal

91-95%

of patients achieved normal PSA values at study conclusion

PSA LEVELS ARE A GOOD INDICATOR OF DISEASE PROGRESSION, BUT MEASURING T LEVELS ENSURES YOUR PATIENTS CONTINUE TO ACHIEVE THE GOALS OF ADT^3,8

Analysis includes 424 patients who achieved castrate T levels by the second dose on the 1-month (n=113), 3-month (n=115), 4-month (n=88), and 6-month (n=108) formulations. Of 424 patients, 2 experienced breakthroughs with peak T >50 ng/dL.³

^‡A breakthrough is defined as a T surge of >50 ng/dL.¹

The importance of nadir T suppression

Low nadir T levels matter in ADT

Multiple studies highlight the importance of nadir T during androgen deprivation therapy^9-11
Leuprolide acetate, the active ingredient in ELIGARD, has been confirmed to achieve and maintain low T levels, with 80% of patients reaching nadir T ≤3 ng/dL when injected subcutaneously³

Current science doesn’t just reflect T targets of <20 ng/dL. It also considers lowest T levels during treatment, also known as nadir T³

A WELL-ESTABLISHED SAFETY PROFILE

Adverse Events for ELIGARD^1§

^§A single event reported as moderate pain resolved within 2 minutes and all 3 mild pain events resolved within several days following injection of ELIGARD 30 mg.¹

^‖Transient pain was reported as mild in intensity in 9 of 10 (90%) events and moderate in intensity in 1 of 10 (10%) events following injection of ELIGARD 45 mg.¹

YOUR PATIENTS RECEIVING SUBCUTANEOUS INJECTIONS MAY REPORT IMMEDIATE TEMPORARY PAIN AT THE INJECTION SITE, UNLIKE PATIENTS RECEIVING INTRAMUSCULAR INJECTIONS, WHO MAY FEEL MUSCLE PAIN THE DAY AFTER^1,12

Over 40 years of efficacy and safety data of leuprolide acetate show a well-established safety profile, with no known drug–drug interactions¹³

Prostate cancer patients have a high risk of potential drug–drug interactions (DDIs) due to the use of treatment combinations, anti-cancer therapies, and the likelihood of comorbid conditions that require drug therapy.¹⁴

DDIs have been reported for GnRH antagonists, anti-androgens, PARP inhibitors, and taxanes, but none are expected for certain GnRH agonists, including leuprolide acetate.¹⁵

ADT, androgen deprivation therapy; PSA, prostate-specific antigen; T, testosterone.

get more WITH ELIGARD, INCLUDING A dosing schedule that works for you and your patients

References: 1. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2024. 2. Shore ND, Chu F, Moul J, et al. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int. 2017;119(2):239-244. 3. Pieczonka CM, Twardowski P, Renzulli J 2nd, et al. Effectiveness of subcutaneously administered leuprolide acetate to achieve low nadir testosterone in prostate cancer patients. Rev Urol. 2018;20(2):63-68. 4. Crawford ED, Hafron JM, Tagawa ST, et al. Impact of late dosing on testosterone suppression with 2 different leuprolide acetate formulations: in situ gel and microsphere. an analysis of United States clinical data. J Urol. 2021;205(2):554-560. 5. Saltzstein D, Shore ND, Moul JW, et al. Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Ther Adv Urol. 2017;10(2):43-50. 6. Sartor O. Eligard^®: a new form of treatment for prostate cancer. Eur Urol Open Sci. 2006;5(18):P905-P910. 7. Data on file. Tolmar, Inc. 2024. 8. Rosario DJ, Davey P, Green J, et al. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol. 2016;34(12):1601-1609. 9. Bryant AK, McKay RR, Kader AK, et al. Subcastrate testosterone nadir and clinical outcomes in intermediate- or high-risk localized prostate cancer. Int J Radiat Oncol Biol Phys. 2019;103(5):1068-1076. 10. Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33(10):1151-1156. 11. Kamada S, Sakamoto S, Ando K, et al. Nadir testosterone after long-term followup predicts prognosis in patients with prostate cancer treated with combined androgen blockade. J Urol. 2015;194(5):1264-1270. 12. Prettyman J, Engel L, Boldt-Houle DM, Atkinson S, Wilt W. Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urologic Nursing. 2019;39(2):83-99. 13. Lupron Depot (leuprolide acetate). Prescribing Information. AbbVie, Inc. 2023. 14. Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):647-661. 15. Ruplin A, Segal E, McFarlane T. Review of drug-drug interactions in patients with prostate cancer. J Oncol Pharm Pract. Published online May 8, 2024.

ELIGARD® is a proven, reliable, and trusted ADT1

Proven efficacy supported by the strongest body of clinical data published in peer-reviewed journals1-7

Backed by an established reputation for advancing the science of prostate cancer*

ELIGARD ACHIEVED PROFOUND T SUPPRESSION ACROSS 1-, 3-, 4-, AND 6-MONTH DOSES

low occurrence of T BREAKTHROUGHS

The importance of nadir T suppression

A WELL-ESTABLISHED SAFETY PROFILE

get more WITH ELIGARD, INCLUDING A dosing schedule that works for you and your patients

IMPORTANT SAFETY INFORMATION

You are now leavingELIGARDhcp.COM

Are you sure you want to leave?

ELIGARD^® is a proven, reliable, and trusted ADT¹

Proven efficacy supported by the strongest body of clinical data published in peer-reviewed journals^1-7

You are now leaving
ELIGARDhcp.COM